Answers are grounded in this paper and cite their sources.
Determine the safety and efficacy of DYNE-101 in adults with myotonic dystrophy type 1 (DM1) in the Phase 1/2 ACHIEVE trial (NCT05481879).
No takes yet. Share an insight, caveat, or question.
Wolf et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: